Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment

Multiple Sclerosis Journal

Volumn 17, Issue 8, 2011, Pages 931-938

  Virta, Jere R ^a   Laatu, Sari ^b,c   Parkkola, Riitta ^a,c   Oikonen, Vesa ^a   Rinne, Juha O ^a   Ruutiainen, Juhani ^b  

^a TURKU PET CENTRE   (Finland)

^b Maskun Neurologinen Kuntoutuskeskus   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

acetylcholinesterase; cognitive impairment; multiple sclerosis; PET

Indexed keywords

ACETYLCHOLINESTERASE; CARBON 11; METHYL 4 PIPERIDINYL PROPIONATE; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; POSITRON EMISSION TOMOGRAPHY;

EID: 80052020022     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511399613     Document Type: Article

References (39)

1. Chiaravalloti N, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 ; 7: 1139-1151
2. Figved N, Klevan G, Myhr K, Glad S, Nyland H, Larsen J, et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand. 2005 ; 112: 463-468 (Pubitemid 41676691)
3. Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci. 2006 ; 245: 177-181 (Pubitemid 43792407)
4. Christodoulou C, MacAllister W, McLinskey N, Krupp L. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?. CNS Drugs. 2008 ; 22: 87-97
5. Ruberg M, Villageois A, Bonnet A, Pillon B, Rieger F, Agid Y. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry. 1987 ; 50: 538-543 (Pubitemid 17067540)
6. Derache N, Marié R, Constans J, Defer G. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci. 2006 ; 245: 103-109 (Pubitemid 43775948)
7. Herholz K. Cognitive dysfunction and emotional-behavioural changes in MS: the potential of positron emission tomography. J Neurol Sci. 2006 ; 245: 9-13 (Pubitemid 43775950)
8. Sørensen P, Jønsson A, Mathiesen H, Blinkenberg M, Andresen J, Hanson L, et al. The relationship between MRI and PET changes and cognitive disturbances in MS. J Neurol Sci. 2006 ; 245: 99-102 (Pubitemid 43775938)
9. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. Nucl Med Biol. 1994 ; 21: 801-808 (Pubitemid 24263573)
10. Iyo M, Namba H, Fukushi K, Shinoto H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 1997 ; 349: 1805-1809 (Pubitemid 27258658)
11. Rinne J, Kaasinen V, Järvenpää T, Någren K, Roivainen A, Yu M, et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 ; 74: 113-115 (Pubitemid 36069048)
12. Bohnen N, Albin R. Cholinergic denervation occurs early in Parkinson disease. Neurology. 2009 ; 73: 256-257
13. Marshall G, Shchelchkov E, Kaufer D, Ivanco L, Bohnen N. White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand. 2006 ; 113: 87-91
14. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009 ; 73: 273-278
15. Bohnen N, Müller M, Kuwabara H, Constantine G, Studenski S. Age-associated leukoaraiosis and cortical cholinergic deafferentation. Neurology. 2009 ; 72: 1411-1416
16. Polman C, Reingold S, Edan G, Filippi M, Hartung H, Kappos L. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846 (Pubitemid 41746873)
17. Kaasinen V, Någren K, Järvenpää T, Roivainen A, Yu M, Oikonen V. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002 ; 22: 615-620 (Pubitemid 35416788)
18. Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Lopresti B, Davis J. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett. 2005 ; 380: 127-132 (Pubitemid 40602342)
19. Meyer J, Gunn R, Myers R, Grasby P. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage. 1999 ; 9: 545-553 (Pubitemid 29372222)
20. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein H, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992 ; 55: 967-972
21. Nagatsuka Si S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, et al. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab. 2001 ; 21: 1354-1366 (Pubitemid 33130947)
22. Sato K, Fukushi K, Shinotoh H, Nagatsuka S, Tanaka N, Aotsuka A, et al. Evaluation of simplified kinetic analyses for measurement of brain acetylcholinesterase activity using N-[11C]Methylpiperidin-4-yl propionate and positron emission tomography. J Cereb Blood Flow Metab. 2004 ; 24: 600-611 (Pubitemid 38725364)
23. Solari A, Mancuso L, Motta A, Mendozzi L, Serrati C. Comparison of two brief neuropsychological batteries in people with multiple sclerosis. Multiple Sclerosis. 2002 ; 8: 169-176 (Pubitemid 34256755)
24. Bombol G, Ikonomidou VN, Pellegrini S, Stern SK, Gallo A, Auh S, et al. Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis. J Neuroimaging 2010: Epub ahead of print.
25. Bohnen N, Kaufer D, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006 ; 253: 242-247 (Pubitemid 43255898)
26. Filippi M, Rocca M. Cortical reorganisation in patients with MS. J Neurol Neurosurg Psychiatry. 2004 ; 75: 1087-1089 (Pubitemid 39005759)
27. Rocca M, Colombo B, Falini A, Ghezzi A, Martinelli V, Scotti G, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005 ; 4: 618-626 (Pubitemid 41317296)
28. Parry A, Scott R, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain. 2003 ; 126: 2750-2760 (Pubitemid 37463093)
29. Zaninotto A, Bueno O, Pradella-Hallinan M, Tufik S, Rusted J, Stough C, et al. Acute cognitive effects of donepezil in young, healthy volunteers. Hum Psychopharmacol. 2009 ; 24: 453-464
30. Krupp L, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004 ; 63: 1579-1585 (Pubitemid 39507572)
31. Greene Y, Tariot P, Wishart H, Cox C, Holt CJ, Schwid S, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol. 2000 ; 20: 350-356 (Pubitemid 30318365)
32. Tsao J, Heilman K. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2005 ; 64: 1823-1823
33. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008 ; 35: 476-481
34. Rorie KD, Strump DA, Douglas JR, Winston-Salem NC. Effects of donepezil on cognitive function in patients with multiple sclerosis. Neurology. 2001 ; 56 (Suppl 3). A99 - A99
35. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology. 2006 ; 50: 540-547
36. Melo J, Sousa C, Garção P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci. 2009 ; 29: 455-464
37. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M. Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. J Neurol. 2006 ; 253: 58-64 (Pubitemid 43157389)
38. Wright C, Geula C, Mesulam M. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993 ; 34: 373-384 (Pubitemid 23259607)
39. Darvesh S, Leblanc A, Macdonald I, Reid G, Bhan V, Macaulay R, et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact. 2010 ; 187: 425-431